Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

prnasiaFebruary 14, 2022

Tag: Proxalutamide , Kintor Pharma , COVID-19

PharmaSources Customer Service